Dose-escalation of Cellistem-OA in Patients With Knee Osteoarthritis

A Phase I Dose-escalation Trial to Assess Safety and Efficacy of Cellistem-OA in Patients With Knee Osteoarthritis (CLT-OA1)

A phase I dose-escalation trial to assess safety and efficacy of allogeneic MSC based-treatment (cellistem-OA) in patients with symptomatic knee osteoarthritis

Inclusion Criteria:

• Patient between 30 and 75 years old
• Knee-OA Kellgren Lawrence grade I to III
• Pain density according to visual analogue scale superior or equal to 50 mm
• Patelar condromalacia grade I to III
• Stable joint with normal physical exploration

Exclusion Criteria:

• Bilateral symptomatic disease
• Local or systemic infection
• Neoplasia
• Immunosuppression state
• Pregnancy
• Anticoagulant therapy
• Other types of arthritis
• Symptomatic disease of hip and/or spine
• Intra-articular infiltration with steroids in the last 3 months
• Intra-articular infiltration with hyaluronic acid in the last 12 months